NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) Short Interest Down 34.8% in August

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 1,500 shares, a decrease of 34.8% from the August 15th total of 2,300 shares. Based on an average daily volume of 4,900 shares, the days-to-cover ratio is currently 0.3 days.

NRx Pharmaceuticals Stock Performance

NRXPW stock traded up $0.01 during trading on Monday, hitting $0.07. 900 shares of the stock traded hands, compared to its average volume of 18,475. NRx Pharmaceuticals has a 1 year low of $0.04 and a 1 year high of $0.39. The firm’s 50 day moving average is $0.07 and its two-hundred day moving average is $0.11.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.